Characterization of Factor VIII Inhibitors

Article

Abstract

Factor VIII (FVIII) inhibitors develop as either alloantibodies against exogenous FVIII in patients with congenital hemophilia A after FVIII-replacement therapy or as autoantibodies against endogenous FVIII in previously healthy, nonhemophilic individuals. The predominant immunoglobulin G (IgG) subclass of FVIII inhibitors is IgG4. The main epitopic regions are known to be located, however, in the A2, A3, and C2 domains. The A2 and A3 epitopes have been identified between amino acid residues 484 and 509 and residues 558 and 565, respectively. Both of these regions are close to the binding sites for activated FIX (FIXa). Two regions have been identified in the C2 domain, one in the amino-terminal portion of the domain (residues 2181-2243) and the other in the carboxy-terminal portion of the domain (residues 2248-2312 and residues 2315-2330). In addition, a crystallographic analysis of a complex of the C2 domain and a human monoclonal IgG4 κ Fab revealed that this type of antibody is in direct contact with hydrophobic and basic residues of the membrane-binding surface. Inactivated FVIII is rapidly cleared from the circulation in the presence of inhibitors.The inhibitors also bind to essential FVIII ligand proteins, including von Willebrand factor, FIXa, FXa, and thrombin, and to surface membrane phospholipid. Some type 2 inhibitors interfere with binding to activated protein C.

Key words

Factor VIII Inhibitor Hemophilia A Alloantibody Autoantibody Epitope Inactivation 

References

  1. 1.
    Kasper CK, Aledort L, Aronson D, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869–872.Google Scholar
  2. 2.
    Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novakova I. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors. Thromb Haemost. 2001;86:1435–1439.PubMedGoogle Scholar
  3. 3.
    Verbruggen B, van Heerde W, Novakova I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost. 2002;88:362–364.PubMedGoogle Scholar
  4. 4.
    White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, for the Factor VIII and Factor IX Subcommittee. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.PubMedGoogle Scholar
  5. 5.
    Yoshioka A, Kamisue S, Tanaka I, et al. Anamnestic response following infusion of prothrombin complex concentrates (PCC) and activated prothrombin complex concentrates (APCC) in haemophilia A patients with inhibitors. Blood Coagul Fibrinolysis. 1991;2(suppl 1):51–58.CrossRefGoogle Scholar
  6. 6.
    Brown DL, Bray GL, Scharrer I. Transient inhibitors in patients with hemophilia A [abstract]. Thromb Haemost. 1999;82(suppl):573. Abstract 1804.Google Scholar
  7. 7.
    Hoyer LW, Gawryl MS, de la Fuente B. Immunochemical characterization of factor VIII inhibitors. Prog Clin Biol Res. 1984;150:73–85.PubMedGoogle Scholar
  8. 8.
    Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood. 1987;69:1475–1480.PubMedGoogle Scholar
  9. 9.
    Matsumoto T, Shima M, Fukuda K, et al. Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease. Thromb Res. 2001;104:381–388.PubMedCrossRefGoogle Scholar
  10. 10.
    Towfighi F, Gharagozlou S, Sharifian RA, et al. Comparative meas urement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. Acta Haematol. 2005;114:84–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Aalberse RC, van der Gaag R, van Leeuwen J. Serologic aspects of IgG4 antibodies, I: prolonged immunization results in an IgG4- restricted response. J Immunol. 1983;130:722–726.PubMedGoogle Scholar
  12. 12.
    Ghosh S, Rizza CR. Changes in the character of factor VIII inhibitors following factor VIII transfusion. Scand J Haematol. 1984;33:239–243.PubMedGoogle Scholar
  13. 13.
    Fulcher CA, deGraaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci U S A. 1985;82:7728–7732.PubMedCrossRefGoogle Scholar
  14. 14.
    Scandella D, DeGraaf Mahoney S, Mattingly M, Roeder D, Timmons L, Fulcher CA. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci U S A. 1988;85:6152–6156.PubMedCrossRefGoogle Scholar
  15. 15.
    Scandella D, Mattingly M, de Graaf S, Fulcher CA. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood. 1989;74:1618–1626.PubMedGoogle Scholar
  16. 16.
    Scandella DH. Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients. Semin Thromb Hemost. 2000;26:137–142.PubMedCrossRefGoogle Scholar
  17. 17.
    Healey JF, Lubin IM, Nakai H, et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem. 1995;270:14505–14509.PubMedCrossRefGoogle Scholar
  18. 18.
    Lubin IM, Healey JF, Barrow RT, Scandella D, Lollar P. Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis. J Biol Chem. 1997;272:30191–30195.PubMedCrossRefGoogle Scholar
  19. 19.
    Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG, Kemball-Cook GA. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood. 1997;89:2413–2421.PubMedGoogle Scholar
  20. 20.
    van den Brink EN, Turenhout EA, Bank CM, Fijnvandraat K, Peters M,Voorberg J. Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain. Blood. 2000;96:540–545.PubMedGoogle Scholar
  21. 21.
    Prescott R, Nakai H, Saenko EL, et al, and the Recombinate and Kogenate Study Groups. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood. 1997;89:3663–3671.PubMedGoogle Scholar
  22. 22.
    Foster PA, Fulcher CA, Houghten RA, de Graaf Mahoney S, Zimmerman TS. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. J Clin Invest. 1988;82:123–128.PubMedCrossRefGoogle Scholar
  23. 23.
    Ware J, Toomey JR, Stafford DW. Localization of a factor VIIIinhibiting antibody epitope to a region between residues 338 and 362 of factor VIII heavy chain. Proc Natl Acad Sci U S A. 1988;85:3165–3169.PubMedCrossRefGoogle Scholar
  24. 24.
    Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII: correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry. 1986;25:505–512.PubMedCrossRefGoogle Scholar
  25. 25.
    Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood. 2002;99:1215–1223.PubMedCrossRefGoogle Scholar
  26. 26.
    Shibata M, Shima M, Morichika S, et al. An alloantibody recognizing the FVIII A1 domain in a patient with CRM reduced haemophilia A due to deletion of a large portion of the A1 domain DNA sequence. Thromb Haemost. 2000;84:442–448.PubMedGoogle Scholar
  27. 27.
    Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, for the Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy, and development of inhibitors. N Engl J Med. 1993;328:453–459.PubMedCrossRefGoogle Scholar
  28. 28.
    Sultan Y, for the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost. 1992;67:600–602.PubMedGoogle Scholar
  29. 29.
    Shima M, Scandella D, Yoshioka A, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost. 1993;69:240–246.PubMedGoogle Scholar
  30. 30.
    Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid- binding site. Blood. 1995;86:1811–1819.PubMedGoogle Scholar
  31. 31.
    Shima M, Nakai H, Scandella D, et al. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor. Br J Haematol. 1995;91:714–721.PubMedCrossRefGoogle Scholar
  32. 32.
    Nogami K, Shima M, Nakai H, et al. Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect. Br J Haematol. 1999;107:196–203.PubMedCrossRefGoogle Scholar
  33. 33.
    Lollar P. Analysis of factor VIII inhibitors using hybrid human/ porcine factor VIII. Thromb Haemost. 1997;78:647–651.PubMedGoogle Scholar
  34. 34.
    Healey JF, Barrow RT, Tamim HM, et al. Residues Glu2181- Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood. 1998;92:3701–3709.PubMedGoogle Scholar
  35. 35.
    Kuwabara I, Maruyama H, Kamisue S, Shima M, Yoshioka A, Maruyama IN. Mapping of the minimal domain encoding a conformational epitope by lambda phage surface display: factor VIII inhibitor antibodies from haemophilia A patients. J Immunol Methods. 1999;224:89–99.PubMedCrossRefGoogle Scholar
  36. 36.
    Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 Å resolution. Nature. 1999;402:439–442.PubMedCrossRefGoogle Scholar
  37. 37.
    Barrow RT, Healey JF, Jacquemin MG, Saint-Remy JM, Lollar P. Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood. 2001;97:169–174.PubMedCrossRefGoogle Scholar
  38. 38.
    Jacquemin MG, Desqueper BG, Benhida A, et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood. 1998;92:496–506.PubMedGoogle Scholar
  39. 39.
    Spiegel PC Jr, Jacquemin M, Saint-Remy JM, Stoddard BL, Pratt KP. Structure of a factor VIII C2 domain-immunoglobulin G4º Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood. 2001;98:13–19.PubMedCrossRefGoogle Scholar
  40. 40.
    van den Brink EN, Turenhout EA, Davies J, et al. Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. Blood. 2000;95:558–563.Google Scholar
  41. 41.
    van den Brink EN, Bril WS, Turenhout EA, et al. Two classes of germline genes both derived from the VH1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII. Blood. 2002;99:2828–2834.PubMedCrossRefGoogle Scholar
  42. 42.
    Zhong D, Saenko EL, Shima M, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood. 1998;92:136–142.PubMedGoogle Scholar
  43. 43.
    Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood. 2000;95:1324–1329.PubMedGoogle Scholar
  44. 44.
    Qian J, Burkly LC, Smith EP, et al. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur J Immunol. 2000;30:2548–2554.PubMedCrossRefGoogle Scholar
  45. 45.
    Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost. 2003;1:1777–1784.PubMedCrossRefGoogle Scholar
  46. 46.
    Pratt KP, Qian J, Ellaban E, et al. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb Haemost. 2004;92:522–528.PubMedGoogle Scholar
  47. 47.
    Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. Epitope repertoire of human CD4+ T cells on the A3 domain of coagulation factor VIII. J Thromb Haemost. 2004;2:1385–1394.PubMedCrossRefGoogle Scholar
  48. 48.
    Hu GL, Okita DK, Conti-Fine BM. T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects. J Thromb Haemost. 2004;2:1908–1917.PubMedCrossRefGoogle Scholar
  49. 49.
    Jones TD, Phillips WJ, Smith BJ, et al. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J Thromb Haemost. 2005;3:991–1000.PubMedCrossRefGoogle Scholar
  50. 50.
    Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A: UK Haemophilia Centre Directors Organization. Thromb Haemost. 1998;79:762–766.PubMedGoogle Scholar
  51. 51.
    Fijnvandraat K, Turenhout EA, van den Brink EN, et al. The missense mutation Arg593 → Cys is related to antibody formation in a patient with mild hemophilia A. Blood. 1997;89:4371–4377.PubMedGoogle Scholar
  52. 52.
    Peerlinck K, Jacquemin MG, Arnout J, et al. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood. 1999;93:2267–2273.PubMedGoogle Scholar
  53. 53.
    Suzuki H, Shima M, Arai M, et al. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes. Thromb Haemost. 1997;77:862–867.PubMedGoogle Scholar
  54. 54.
    Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood. 1982;60:1103–1109.PubMedGoogle Scholar
  55. 55.
    Nogami K, Shima M, Giddings JC, et al. Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysis. Blood. 2001;97:669–677.PubMedCrossRefGoogle Scholar
  56. 56.
    Walker FJ, Scandella D, Fay PJ. Identification of the binding site for activated protein C on the light chain of factors V and VIII. J Biol Chem. 1990;265:1484–1489.PubMedGoogle Scholar
  57. 57.
    Nogami K, Shima M, Nishiya K, et al. A novel mechanism of factor VIII protection by von Willebrand factor from activated protein Ccatalyzed inactivation. Blood. 2002;99:3993–3998.PubMedCrossRefGoogle Scholar
  58. 58.
    van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem. 1981;256:3433–3442.PubMedGoogle Scholar
  59. 59.
    Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C: cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest. 1988;82:1236–1243.PubMedCrossRefGoogle Scholar
  60. 60.
    Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem. 1996;271:27424–27431.PubMedCrossRefGoogle Scholar
  61. 61.
    Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem. 1988;263:5230–5234.PubMedGoogle Scholar
  62. 62.
    Leyte A, Mertens K, Distel B, et al. Inhibition of human coagulation factor VIII by monoclonal antibodies: mapping of functional epitopes with the use of recombinant factor VIII fragments. Biochem J. 1989;263:187–194.PubMedGoogle Scholar
  63. 63.
    Shima M, Yoshioka A, Nakai H, et al. Epitope localization of monoclonal antibodies against factor VIII light chain which inhibit complex formation by factor VIII with von Willebrand factor. Int J Hematol. 1991;54:515–522.PubMedGoogle Scholar
  64. 64.
    Jacquemin M, Benhida A, Peerlinck K, et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood. 2000;95:156–163.PubMedGoogle Scholar
  65. 65.
    Lenting PJ, van de Loo JW, Donath MJ, van Mourik JA, Mertens K. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem. 1996;271:1935–1940.PubMedCrossRefGoogle Scholar
  66. 66.
    Fay PJ, Beattie T, Huggins CF, Regan LM. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem. 1994;269:20522–20527.PubMedGoogle Scholar
  67. 67.
    Fijnvandraat K, Celie PH, Turenhout EA, et al. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. Blood. 1998;91:2347–2352.PubMedGoogle Scholar
  68. 68.
    Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem. 1998;273:19049–19054.PubMedCrossRefGoogle Scholar
  69. 69.
    Fay PJ, Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem. 1999;274:29826–29830.PubMedCrossRefGoogle Scholar
  70. 70.
    Parker ET, Pohl J, Blackburn MN, Lollar P. Subunit structure and function of porcine factor Xa-activated factor VIII. Biochemistry. 1997;36:9365–9373.PubMedCrossRefGoogle Scholar
  71. 71.
    Nogami K, Shima M, Hosokawa K, et al. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol Chem. 2000;275:25774–25780.PubMedCrossRefGoogle Scholar
  72. 72.
    Nogami K, Shima M, Hosokawa K, et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem. 1999;274:31000–31007.PubMedCrossRefGoogle Scholar
  73. 73.
    Nogami K, Shima M, Nishiya K, et al. Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism. Thromb Haemost. 2002;87:459–465.PubMedGoogle Scholar
  74. 74.
    Nogami K, Shima M, Nishiya K, et al. Anticoagulant effects of a synthetic peptide containing residues Thr-2253-Gln-2270 within factor VIII C2 domain that selectively inhibits factor Xa-catalysed factor VIII activation. Br J Haematol. 2002;116:868–874.PubMedCrossRefGoogle Scholar
  75. 75.
    Nogami K, Lapan KA, Zhou Q, Wakabayashi H, Fay PJ. Identification of a factor Xa-interactive site within residues 337-372 of the factor VIII heavy chain. J Biol Chem. 2004;279:15763–15771.PubMedCrossRefGoogle Scholar
  76. 76.
    Nogami K, Freas J, Manithody C, Wakabayashi H, Rezaie AR, Fay PJ. Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain. J Biol Chem. 2004;279:33104–33113.PubMedCrossRefGoogle Scholar
  77. 77.
    Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. Science. 1986;234:1566–1570.PubMedCrossRefGoogle Scholar
  78. 78.
    Lacroix-Desmazes S, Bayry J, Misra N, et al. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med. 2002;346:662–667.PubMedCrossRefGoogle Scholar
  79. 79.
    Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Catalytic antibodies to factor VIII in haemophilia A. Blood Coagul Fibrinolysis. 2003;14(suppl 1):S31-S34..PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  1. 1.Department of PediatricsNara Medical UniversityNaraJapan

Personalised recommendations